msk-2206 Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1
  • InChIKey: ULDXWLCXEDXJGE-UHFFFAOYSA-N
  • Mol. Mass: 407.48
  • ALogP: 4.24
  • ChEMBL Molecule:
    mk-2206  
More Chemistry

Pharmacology

Alternative names

mk2206 | mk 2206 | mk-2206 | msk-2206

Organizations (30)

Research & Development (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (76)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (76)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma, Bronchiolo-Alveolar (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Bile Duct Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Breast Neoplasms, Male (Phase 1)

Burkitt Lymphoma (Phase 1)

Carcinoma, Adenoid Cystic (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cholangiocarcinoma (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Gallbladder Neoplasms (Phase 2)

Glioma (Phase 2)

Hamartoma (Phase 2)

Hemangiosarcoma (Phase 2)

Hodgkin Disease (Phase 2)

Intestinal Neoplasms (Phase 2)

Intraocular Lymphoma (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 1)

Leukemia, Eosinophilic, Acute (Phase 1)

Leukemia, Hairy Cell (Phase 2)

Leukemia, Large Granular Lymphocytic (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Leukemia, Mast-Cell (Phase 1)

Leukemia, Monocytic, Acute (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Leukemia, Myelomonocytic, Juvenile (Phase 1)

Leukemia, Neutrophilic, Chronic (Phase 1)

Leukemia, Prolymphocytic (Phase 1)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Lymphomatoid Granulomatosis (Phase 2)

Melanoma (Phase 2)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreas (Phase 2)

Pancreatic Neoplasms (Phase 2)

Plasmacytoma (Phase 1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Salivary Gland Neoplasms (Phase 2)

Sezary Syndrome (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 2)

Testicular Neoplasms (Phase 2)

Thymoma (Phase 2)

Transplantation (Phase 1)

Uterine Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 49
  • # of Trial Organizations: 30

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue